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Themetabolic state of quiescent hematopoietic stem
cells (HSCs) is an important regulator of self-renewal,
but it is unclear whether or how metabolic parame-
ters contribute to HSC lineage specification and
commitment. Here, we show that the commitment
of human and murine HSCs to the erythroid lineage
is dependent upon glutamine metabolism. HSCs
require the ASCT2 glutamine transporter and active
glutamine metabolism for erythroid specification.
Blocking this pathway diverts EPO-stimulated
HSCs to differentiate into myelomonocytic fates,
altering in vivo HSC responses and erythroid
commitment under stress conditions such as
hemolytic anemia. Mechanistically, erythroid specifi-
cation of HSCs requires glutamine-dependent de
novo nucleotide biosynthesis. Exogenous nucleo-
sides rescue erythroid commitment of human HSCs
under conditions of limited glutamine catabolism,
and glucose-stimulated nucleotide biosynthesis
further enhances erythroid specification. Thus, the
availability of glutamine and glucose to provide fuel
for nucleotide biosynthesis regulates HSC lineage
commitment under conditions of metabolic stress.
INTRODUCTION
Extensive research during the past decades has focused on
elucidating the roles of cytokines and the microenvironment in
the proliferation and differentiation of hematopoietic stem cells
(HSCs). However, it is only in the past few years that nutrient
resources and their transport have emerged as key regulators
of HSC survival and proliferation. Increasing glucose meta-
bolism, through the de novo synthesis and/or translocation of
glucose transporters to the cell surface, is thought to be crucialCfor the activation and cell cycle entry of hematopoietic progeni-
tors. HSCs reside in a hypoxic environment and several recent
studies have elegantly shown that this environment, conducive
to high rates of glycolysis, is required for stem cell maintenance
(Majeti et al., 2007;Miharada et al., 2011; Simsek et al., 2010; Ta-
kubo et al., 2013; Yu et al., 2013). Indeed, HSCs have a lowmito-
chondrial mass and mutations in genes such as PTEN-like
mitochondrial phosphatase that enhance glycolysis and lower
oxidative phosphorylation (OXPHOS) (Yu et al., 2013) increase
HSC numbers and inhibit hematopoietic differentiation. Further-
more, elevated levels of pyruvate dehydrogenase kinase (Pdk),
which increase glycolysis, augment stem cell potential, whereas
loss of Pdk function attenuates glycolysis and HSC reconstitu-
tion capacity (Takubo et al., 2013). Thus, factors that modulate
the balance between mitochondrial and nonmitochondrial meta-
bolism control HSC function.
HSC renewal is also regulated by the fuel type that is used by
the cell. Recent work has shown that fatty acid oxidation (FAO) is
required for optimal HSCmaintenance. Activation of FAO results
in an asymmetric division and self-renewal while its inhibition
leads to a symmetric, differentiating division (Ito et al., 2012).
Thus, different metabolic pathways such as glucose-driven
glycolysis and FAO play key roles in HSC stemness and the
decision of an HSC to undergo self-renewal as compared to dif-
ferentiation. Nevertheless, it is not known whether metabolic
pathways regulate the commitment of an HSC to a specific line-
age fate.
Cell differentiation is generally associated with proliferation and
increasedmetabolic requirements that can beprovidedby energy
sources such asglucose, fatty acids, lactate, or glutamine, among
others (reviewed inVanderHeidenetal., 2009).Glucoseandgluta-
mine metabolism are interrelated: glutamine transport is the rate-
limiting step in the activation ofmTOR, andmTORupregulates the
Glut1 glucose transporter and glucose transport (Fuchs et al.,
2007; Nicklin et al., 2009; Sundrud et al., 2009). While glucose
and glutamine are both precursors in the tricarboxylic acid (TCA)
cycle, aswell asprecursors in theproductionof lipids, nucleotides,
and amino acids, their relative contributions to metabolic path-
ways driving HSC lineage commitment remain undefined.ell Stem Cell 15, 169–184, August 7, 2014 ª2014 Elsevier Inc. 169
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Metabolic Regulation of HSC Lineage CommitmentThe Glut1 glucose transporter is only upregulated during the
final mitoses of HSC-driven erythroid differentiation (Montel-Ha-
gen et al., 2008a, 2008b, 2009a, 2009b). Thus, other nutrients are
likely to regulate HSC lineage commitment. Here, we demon-
strate that the expression and function of the ASCT2 glutamine
transporter (also known as SLC1A5) on HSCs is critical for
erythroid lineage specification. Blocking glutamine metabolism
completely abrogated the erythroid differentiation of human
CD34+ progenitors and severely attenuated murine erythropoi-
esis under stress conditions and during the newborn period.
Commitment to an erythroid fate was not restored by bypassing
the glutamine-based fueling of the TCA cycle, but rather was
strictly dependent on glutamine-supported de novo nucleotide
biosynthesis. Moreover, erythroid commitment was associated
with an increased shunting of glucose through the pentose phos-
phate pathway (PPP), resulting in the synthesis of five-carbon
sugars used for nucleotide biosynthesis. Treatment of erythro-
poietin-induced HSCs with the 2-deoxyglucose (2-DG) analog
further promoted shunting of glucose through this pathway,
enhancing the magnitude and kinetics of HSC erythroid commit-
ment. In contrast, under conditions of limiting nucleotide
biosynthesis, HSCs were not able to undergo erythroid differen-
tiation andwere diverted to amyelomonocytic cell fate. Thus, our
data point to the critical nature of metabolic pathways in regu-
lating HSC lineage specification.
RESULTS
High Expression of the ASCT2Glutamine Transporter on
CD34+CD38–Lin– Human HSCs Is Maintained during
Erythroid Commitment
Previous data showing that the Glut1 glucose transporter is not
significantly expressed on hematopoietic progenitors and is
only upregulated during late stages of human erythropoiesis sug-
gested that alternative nutrient transporters may be implicated in
HSC quiescence and lineage commitment (Montel-Hagen et al.,
2008a, 2008b, 2009a, 2009b; Ogawa, 2008). Indeed, we did not
detect Glut1 on either CD34+CD38HSCs or more differentiated
CD34+CD38+ progenitors. However, the ASCT2 glutamine trans-
porter was expressed at significant levels on both subsets (Fig-
ure 1A). Furthermore, ASCT2 levels were not markedly altered
during recombinant erythropoietin (rEPO)-induced erythroid
lineage commitment (Figure 1B). Surface expression correlated
with transcript levels; rEPO-induced erythropoiesis resulted in
80- and 40-fold increases in Glycophorin A (GlyA) and Glut1
mRNAs, respectively, whereas Asct2 levels were modulated by
only 2-fold (Figure S1A available online).Figure 1. Downregulation of ASCT2 in CD34+CD38– Progenitors Sever
(A) Cell surface expression of the Glut1 and ASCT2 transporters was monitored
tograms showing control (shaded) and specific (heavy line) stainings on CD34+C
presented.
(B) The evolution of Glut1 and ASCT2 during the rEPO-induced (3 U/ml) erythroid d
(GlyA) red cell marker. Cell surface staining at days 2, 4, 7, and 10 of erythroid d
(C) Progenitors were transduced with control-GFP, shGlut1-GFP, or shASCT2-GF
GFP expression as shown in the indicated gates (top plots). Nontransduced and
expression was monitored and the level of erythroid differentiation was assessed
(D) Transduced progenitors were cultured in the absence or presence of rEPO (left
was followed and the percentages of GFP+ cells relative to day 2 of transductio
experiments.
CshRNA-Mediated Knockdown of ASCT2 Alters HSC
Lineage Commitment
In order to assess the specific effects of Glut1 and ASCT2 on the
differentiation of progenitors toward an erythroid lineage fate, we
pursued an shRNA-mediated knockdown approach. CD34+
progenitors were transduced at a more than 30% efficiency (Fig-
ure S1B), resulting in the specific downregulation of ASCT2 or
Glut1 in shASCT2-GFP or shGlut1-GFP-transduced progenitors,
respectively (Figures S1C and S1D; 90%and 60%, respectively).
Notably, the EPO-induced lineage commitment of the most
immature CD34+CD38Lin progenitors toward the erythroid
lineage was severely attenuated by ASCT2 downregulation.
Only 10% of shASCT2-transduced cells acquired expression
of the GlyA marker following 6 days of differentiation as
compared to 40%–80% of control or shGlut1-transduced
HSCs (Figure 1C). Furthermore, ASCT2 knockdown resulted in
a significant skewing of CD34+CD38 progenitors to the myeloid
lineage, even in the presence of rEPO. Specifically, approxi-
mately 50% of shASCT2-transduced progenitors upregulated
the CD11b myeloid marker as compared to only 5%–21% of
cells in control-GFP and shGlut1-transduced subsets (Fig-
ure 1C). Altogether, these data point to the importance of
ASCT2 in the erythroid commitment of primitive progenitors.
The downregulation of ASCT2 was also associated with a
massive selective disadvantage following rEPO stimulation; the
percentages of GFP+ cells decreased by 50% between days 2
and 4 of differentiation and by 85%by day 7 (Figure 1D). Interest-
ingly, progenitors in which Glut1 was downregulated were also
negatively selected, but erythroid differentiation was not signifi-
cantly compromised (Figures 1C and 1D). In the absence of
rEPO, decreases in the percentages of shGlut1-GFP+ and
shASCT2-GFP+ progenitors were only gradual, similar to that
detected in control GFP-transduced cells (Figure 1D). These
data suggest that the optimal expression of ASCT2 and Glut1
transporters is not required for progenitor cell expansion. How-
ever, the two transporters play critical and nonredundant roles
in supporting the erythroid commitment of HSCs.
Blocking Glutamine Utilization Abrogates the Erythroid
Differentiation Potential of CD34+ Progenitors and
Promotes Myeloid Differentiation
While ASCT2 transports glutamine, it also transports other
neutral amino acids (Kanai and Hediger, 2004). It was therefore
important to assess whether the role of ASCT2 in the erythroid
lineage commitment of CD34+ progenitors was due to its
capacity to transport glutamine. To address this question, we
blocked glutaminolysis with 6-diazo-5-oxo-L-norleucine (DON),ely Attenuates rEPO-Induced Erythroid Differentiation
on CD34+ progenitors as a function of CD38 expression. Representative his-
D38 stem cells as well as more differentiated CD34+CD38+ progenitors are
ifferentiation of CD34+ progenitors wasmonitored relative to the Glycophorin A
ifferentiation are presented.
P lentiviral vectors and CD34+CD38 HSCs were FACS-sorted on the basis of
transduced progenitors were cultured in the presence of rEPO for 6 days. GFP
as a function of GlyA relative to the CD11b myeloid marker.
and right panels, respectively). The evolution of shRNA-expressing progenitors
n are noted. Results are representative of data obtained in three independent
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Figure 2. Blocking Glutamine Utilization Abrogates the Erythroid Differentiation Potential of CD34+CD38– and CD34+CD38+ Progenitors and
Promotes Their Myeloid Differentiation
(A) CD34+ progenitors were stimulated with rEPO in the absence or presence of the 6-diazo-5-oxo-L-norleucine (DON) glutamine analog (50 mM). Expression of
the GlyA and CD36 erythroid markers was monitored at the indicated days. Representative histograms showing expression in the absence of rEPO (blue),
presence of rEPO (red), and presence of both rEPO and DON (black) are shown.
(B) Representative dot plots showing the percentages of FSClo and FSClo/a4 integrinlo cells, correlating with increasing erythroid differentiation, are presented.
(C) Expression of the Glut1 and ASCT2 transporters wasmonitored at day 10 of differentiation. Solid black histograms denote Glut1 and ASCT2 staining and gray
histograms show nonspecific staining.
(D) Expression of the CD11b and CD13 myeloid markers, not expressed on erythroid lineage cells, was monitored at the indicated time points. Forward scatter
(FSC) and side scatter (SSC), roughly representing size and granularity, were monitored at day 13 of differentiation. Results are representative of data obtained in
three independent experiments.
(E) Differentiation of FACS-sorted CD34+CD38Lin and CD34+CD38+Lin progenitors was assessed in the presence or absence of DON. Representative dot
plots showing expression of CD36, CD71, GlyA, and CD11b are presented and the percentages of cells in each quadrant are indicated.
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Metabolic Regulation of HSC Lineage Commitmenta mitochondrial glutaminase inhibitor that functions only when
the enzyme is active (Curthoys and Watford, 1995). Importantly,
treatment of CD34+ progenitors with this glutaminase inhibitor172 Cell Stem Cell 15, 169–184, August 7, 2014 ª2014 Elsevier Inc.completely abrogated erythroid lineage commitment, as shown
by an absence of GlyA and CD36 in rEPO-stimulated cultures
(Figure 2A). We also studied the status of these progenitors by
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Metabolic Regulation of HSC Lineage Commitmentassessing forward scatter and a4 integrin expression; reductions
in these two parameters correspond to terminal erythroid differ-
entiation (Hu et al., 2013). Under conditions where DON was
used to block glutaminase activity, FSC and a4 integrin levels re-
mained elevated during the entire period of rEPO induction (Fig-
ure 2B). Furthermore, while ASCT2 was not affected by either
lineage differentiation or glutamine utilization, surface Glut1
expression, associated with late erythroid differentiation, was
not induced in the presence of DON (Figure 2C).
In accordwith theASCT2 knockdown experiments (Figure 1C),
DON-treated CD34+ progenitors differentiated toward the mye-
lomonocytic lineage even in the presence of rEPO. This was
assessed by CD11b and CD13 expression, together with high
forward scatters (FSCs) and side scatters (SSCs) (Figure 2D).
Importantly, EPO-induced CD34+CD38 HSCs as well as more
mature CD34+CD38+ progenitors were diverted to a myeloid
cell fate in the presence of DON (Figure 2E). Furthermore, DON
treatment also promoted myeloid cell differentiation during
cytokine-driven expansion (Figure S2A). Thus, inhibiting gluta-
mine metabolism reorients the lineage potential of primitive
progenitors to a myeloid fate, even in the presence of high doses
of rEPO.
To determine whether glutaminemetabolism is important at all
stages of erythroid differentiation, we carried out experiments
wherein DON was added in undifferentiated progenitors as
compared to progenitors that had already initiated an erythroid
lineage commitment. These data showed that glutaminolysis is
critical during early erythroid commitment but is not required
once lineage fate is underway (Figure S2B). Furthermore, the
results of DON are reversible; following removal of DON, progen-
itors acquired expression of erythroid lineage markers (Fig-
ure S2B). These data indicate that glutamine catabolism is
required at early stages of HSC commitment to the erythroid
lineage.
Treatment of Human Hematopoietic Progenitors with
2-DG Enhances rEPO-Induced Erythroid Commitment
Given the critical role of glutamine in the erythroid commitment of
HSCs, it was of interest to evaluate the importance of glucose
utilization in this process. We therefore assessed whether
blocking glucose catabolism with 2-DG alters the fate of EPO-
induced HSCs. CD34+ hematopoietic progenitors were differen-
tiated in the presence of the nonmetabolizable 2-DG analog,
under conditions where extracellular glucose and glutamine con-
centrations were maintained. Although Glut1-downregulated
cells were counter-selected upon EPO treatment (Figure 1D),
erythroid differentiation was actually enhanced in the presence
of 2-DG (Figure 3A).
The vast majority of progenitors were already GlyA+ at day 3 of
differentiation in the presence of 2-DG (73%) as compared to
36% following induction with rEPO alone. The augmented
erythroid differentiation was also demonstrated by the more
rapid reduction in FSCs and SSCs and the loss of a4 integrin
(Figures 3B and 3C). Furthermore, 2-DG treatment resulted in
increased GlyA, b-globin, and Glut1 mRNAs and protein (Figures
3D and 3E). While the erythroid-enhancing effect of 2-DG was
maximal at 1 mM, it was also observed at a concentration of
0.2 mM (Figure 3F). Terminal erythroid differentiation could be
detected on a visual level, as demonstrated by cell pellets withCa darker red color (Figure 3G). Furthermore, stained cytospins
revealed more extensive erythroblast differentiation and
enucleation in the presence of 2-DG (12%–26% as compared
to 4%–8% in independent experiments; Figure 3H). Interestingly
though, the enhancing effect of 2-DG on erythroid commitment
was not detected in the presence of DON (Figure S4). Thus,
the effects of blocking glutaminolysis are dominant over
glucose catabolism, at least in the context of erythroid lineage
commitment.
The presence of 2-DG did not negatively impact on the prolif-
eration of erythroid progenitors except at the highest dose
(2.5 mM). Interestingly, nonerythroid progenitors were signifi-
cantly more sensitive to the effects of 2-DG than their erythroid
counterparts were (Figure S3B). These data suggest that the
differential effects of 2-DG reflect a switch in the metabolic
program of hematopoietic progenitors engaged toward an
erythroid cell fate.
The In Vivo Commitment of Hematopoietic Precursors to
an Erythroid versus Myeloid Fate Is Regulated by
Glucose and Glutamine Metabolism
In order to determine how glucose and glutamine metabolism
impact on the in vivo commitment of HSCs under stress condi-
tions, we induced a hemolytic anemia in adult mice by phenylhy-
drazine (PHZ) injection under conditions where glycolysis or
glutaminolysis was blocked with 2-DG and DON, respectively.
PHZ-injected mice showed an important rebound erythropoiesis
by day 5 and at this time point, hematocrits (Hcts) in control and
2-DG-treated anemic mice recovered to similar levels (Hct range
of 25–35) whereas the Hcts in DON-treated mice were markedly
reduced (9–10, Figure 4A). The response to anemia could also be
discerned by the impressive splenomegaly in control and 2-DG-
treated anemic mice, which was not detected in DON-treated
animals. Rebound erythropoiesis corresponded to increased
percentages of splenic Ter119+ erythroid progenitors (up to
85%–90%) as compared with DON-treated mice where no
induction was detected (mean of 33%), and a similar trend was
detected in the bone marrow (BM; Figure 4A). Notably, the
effects of glutamine metabolism on the erythroid commitment
of hematopoietic progenitors were specific to conditions of
stress because DON treatment of nonanemic control mice did
not alter the percentages of Ter119+ cells in either BM or spleen
(means of 54%–58% in BM and 42%–49% in spleen; Figure 4A).
To further assess erythroid lineage differentiation, we
evaluated Ter119+ cells on the basis of CD44/FSC staining
(Chen et al., 2009) with stages I and V representing the most un-
differentiated and differentiated cells, respectively (Figure S5A).
Following induction of anemia, the percentages of stage I–III pro-
genitors were actually >10% higher in 2-DG-treated mice than in
control anemic mice (mean of 70% compared to 60%, p < 0.05)
with markedly lower levels in DON-treated mice (mean of 28%;
Figure 4B). Thus, blocking glutamine metabolism inhibits the
capacity of anemic mice to induce a rebound erythropoiesis.
Notably, the drastic anemia in DON-treated mice was not due
to a global effect on HSCs because the percentages of BM
progenitors were similar in all groups (evaluated on the basis of
a LinSca1+c-Kit+ phenotype; 5%–8%; Figure 4C) and B and
T lymphoid cells were not significantly affected (Figure S5B).
Moreover, the presence of short-lived Gr1+ cells, requiring anell Stem Cell 15, 169–184, August 7, 2014 ª2014 Elsevier Inc. 173
Figure 3. 2-Deoxyglucose Enhances In Vitro Erythropoiesis in a Dose-Dependent Manner
(A) Erythroid lineage commitment was assessed in the presence of the 2-deoxyglucose analog (2-DG; 1 mM). Representative histograms of GlyA expression are
shown at the indicated time points.
(B) Expression of a4 integrin as a function of FSC is shown at days 6 and 10 of differentiation.
(legend continued on next page)
Cell Stem Cell
Metabolic Regulation of HSC Lineage Commitment
174 Cell Stem Cell 15, 169–184, August 7, 2014 ª2014 Elsevier Inc.
Cell Stem Cell
Metabolic Regulation of HSC Lineage Commitmentongoing HSC differentiation, was significantly higher in the BM
and spleens of DON-treated anemic mice as compared to con-
trol and 2-DG-treated mice (Figures 4D and S5B; p < 0.001).
Thus, these data are in complete accord with the increased
ex vivo myeloid differentiation of human progenitors observed
in the presence of DON.
We next evaluated the in vivo effects of altering glucose and
glutamine metabolism in newborn mice because during this
stage of life, there is an active lineage commitment of HSCs
with a high level of erythroid differentiation. Newborn mice
were injected with either 2-DG or DON on postnatal days 3
and 5 and sacrificed on day 6. The percentages of splenic
Ter119+ cells were equivalent in control and 2-DG-treated
pups (means of 80% and 84%) but were significantly lower in
DON-treated mice (57%; p < 0.0001; Figure 5A). Furthermore,
while the vast majority of Ter119+ cells in control and 2-DG-
treated pups were at early stages of erythropoiesis (>90%;
mean of 94%), erythroid commitment in the presence of DON
was attenuated (Figure 5B). Accordingly, postnatal erythropoi-
esis, distinguished from prenatal erythropoiesis by loss of the
Glut1 transporter (Montel-Hagen et al., 2008a, 2008b), was
significantly reduced in the presence of DON (p < 0.0001; Fig-
ure 5B). Thus, these data demonstrate that blocking glutamine
metabolism, but not glucose metabolism, severely impedes
the postnatal commitment of HSCs to an erythroid lineage fate.
Glucose catabolism was however critical for myeloid lineage
commitment during the immediate postnatal period. Treatment
with the 2-DG glucose analog resulted in marked decreases
in Gr1+ as well as CD11b+ cells, whereas in the presence of
DON, Gr1+ cells were significantly increased (p < 0.001 for
both conditions; Figure 5C). Thus, 2-DG and DON treatments
have opposing effects on the myeloid lineage differentiation of
HSCs in vivo. These data together with our ex vivo human
progenitor differentiation experiments reveal a conservation in
the metabolic constraints regulating the differentiation of human
and murine HSCs to erythroid and myelomonocytic cell fates.
Commitment of Human Hematopoietic Progenitors to
the Erythroid Lineage Requires Glutamine-Dependent
Nucleotide Biosynthesis
To better elucidate the mechanism or mechanisms via which
glutamine supports the erythroid lineage specification of HSCs,
we evaluated the metabolic pathways fueled by glutamine. The
role of glutamine in supporting the TCA cycle (anaplerosis) dur-
ing erythropoiesis was evaluated by means of high performance
liquid chromatography mass spectrometry (HPLC-MS). Gluta-
mine, uniformly labeled with heavy carbon (13C) and nitrogen
(15N) atoms, was traced intracellularly for 24 hr. The conversion
of labeled glutamine into the TCA intermediate a-ketoglutarate(C) FSC and SSC were monitored under the conditions described above and rep
(D) Expression of the Glut1 and ASCT2 transporters was monitored in the presen
denote Glut1 and ASCT2 staining and thin line histograms depict control staining
(E) GlyA, Glut1, and b-globin transcripts were quantified by qRT-PCR and mean
(F) Differentiation was induced by rEPO in the presence of 0, 0.2, 1, or 2.5 mM of 2
day 6 of differentiation and representative histograms are shown.
(G) Following rEPO-induced erythroid differentiation in the presence of 0, 0.2, 1,
were photographed (day 10 of differentiation).
(H) Representative images of May-Gru¨nwald-Giemsa staining of cytospins, obta
C(aKG) can be monitored by assessing the percentage of aKG
incorporating 13C atoms. Importantly, we found that EPO-
induced erythropoiesis resulted in a significant increase in
glutamine-derived aKG, as shown by the relative abundance of
the fully labeled isotopomer (13C5), in the absence or presence
of 2-DG (Figure 6A). In contrast, and as expected, the anaplerotic
contribution of glutamine was severely impaired in the presence
of DON (Figure 6A).
The generation of aKG from glutamine occurs via the deami-
nation of glutamate, a reaction catalyzed by either glutamate
dehydrogenase (GDH) or transaminases (Figure 6B). We found
that expression of GDH and the production of alanine, a byprod-
uct of the transaminase-mediated generation of aKG, were
increased during erythroid differentiation (Figures 6A and 6C).
The latter result pointed to the importance of transaminases in
the erythroid commitment of HSCs and indeed, the aminooxy-
acetic acid (AOA) pan transaminase inhibitor (Moreadith and
Lehninger, 1984) completely suppressed EPO-induced differen-
tiation (Figure 6D). Notably, erythroid commitment was restored
by supplementation with a cell-permeable ester (dimethyl a-ke-
toglutarate [DMK]; Figure 6D), indicating a critical role for trans-
aminase-derived aKG in supporting erythropoiesis.
On the basis of these data, wewere surprised to find that EPO-
induced erythropoiesis was sustained in the absence of extra-
cellular glutamine (Figure 6E). However, glutamine can be
synthesized intracellularly from glutamate, via glutamine synthe-
tase (GS; Figure 6B). As such, we blocked this pathway using
methionine sulfoximine (MSO), a GS inhibitor (Berlicki, 2008),
and completely abrogated erythroid commitment (Figure 6E).
These experiments reveal endogenous glutamine biosynthesis
to be required for differentiation under conditions where extra-
cellular glutamine is absent. Indeed, GS is highly expressed dur-
ing erythropoiesis (data not shown). These findings demonstrate
that glutamine itself, rather than its anaplerotic derivatives, is
required for erythroid differentiation.
In addition to its role in feeding the TCA cycle, glutamine
directly feeds the de novo biosynthesis of nucleotides and indi-
rectly contributes carbons and nitrogens to the biosynthesis of
pyrimidines. The simultaneous tracing of glutamine carbons
and nitrogens revealed that EPO significantly stimulated the
de novo synthesis of purine and pyrimidine nucleotides. A
similar high level of incorporation of 15N in ATP and 15N/13C
in UTP was detected in the presence of 2-DG (Figure 6F).
Due to its competitive inhibition of glutaminase, DON inhibits
the glutamine-dependent reactions required for nucleotide
biosynthesis (Levitzki and Koshland, 1971); Figure 6B). In
fact, the presence of DON almost completely abrogated de
novo synthesis of UTP and ATP, as shown by an absence of
nitrogen and carbon incorporation (Figure 6F). In line withresentative histograms at day 10 of differentiation are shown.
ce or absence of rEPO and 2-DG (day 10) as indicated. Solid black histograms
.
levels relative to 18S or actin are presented. *p < 0.05.
-DG as indicated. FSC, GlyA, Glut1, and ASCT2 expression were monitored at
or 2.5 mM of 2-DG, cells were centrifuged in 96-well conical plates and pellets
ined at day 10 in the indicated conditions, are shown.
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Figure 4. In Vivo Inhibition of Glutaminolysis Severely Attenuates Stress Erythropoiesis following Induction of Anemia
(A) Anemia was induced in adult mice by phenylhydrazine (PHZ) injection at days 0, 1, and 3 (40 mg/kg). For the alteration of glucose or glutamine metabolism,
mice were injected with 2-DG (0.5 g/kg) and DON (1.5 mg/kg), respectively, at days 2 and 4. Hematocrits in control, 2-DG-, and DON-treated mice following PHZ
injection are shown at day 5 (left panel) and spleens frommice in all three groups are presented (middle panel). Representative plots showing the percentages of
Ter119+ erythroid cells in the spleen are presented (bottom plots) and quantification of levels in BM and spleens are presented with each point corresponding to
data from a single mouse (right panels). Results are representative of data from three independent experiments.
(B) Quantification of immature erythroid subsets (populations I–III) is shown with each point representing data from a single mouse.
(C) The presence of HSCs in treated mice was assessed within the lineage-negative immature BM population. The percentages of c-Kit+/Sca-1+ progenitors are
compared with control mice. Ter119-expressing cells in the BM are presented relative to Gr1+ myeloid cells.
(D) Quantification of the percentages of Gr1+ and CD11b+ cells in spleens is presented with each point corresponding to data from one mouse and mean
percentages are shown as solid lines. **p < 0.01; ***p < 0.001.
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lated by EPO led to a more pronounced consumption of
serine, whose carbons are essential to nucleotide biosynthesis
(Figure 6F).
Given the inhibitory effect of DON on multiple reactions of
glutamine metabolism (Figure 6B), we attempted to determine176 Cell Stem Cell 15, 169–184, August 7, 2014 ª2014 Elsevier Inc.which pathway was critical for the erythroid commitment of
HSCs. Supplementing cells with DMK and thereby bypassing
the DON-mediated impairment to the TCA cycle did not
restore erythropoiesis (Figure 6G). However, supplementation
of DON-treated cells with nucleosides rescued erythropoiesis,
demonstrating the critical nature of glutamine-supported
Figure 5. Glycolysis and Glutaminolysis
Play Opposing Roles in Fostering In Vivo
Myeloid and Erythroid Differentiation during
Newborn Development
(A) Mice pups were injected with 2-DG (0.25 g/kg)
or DON (0.75 mg/kg) at days 2 and 4 of life. At day
5, mice in the 2-DG group were moribund and all
animals were sacrificed. Representative dot plots
showing Ter119+ cells as a function of CD44 are
shown and the relative percentages of Gr1+ and
Ter119+ cells are presented. Quantification of the
percentages of Ter119+ cells in spleens of mice
from each group is presented with each point
representing an individual mouse.
(B) Erythroblast differentiation, as a function of
CD44/FSC staining within the Ter119+ subset,
is shown in representative dot plots. The percent-
ages of Glut1+ and Glut1 cells within mature
erythroid cells (population V), corresponding to
prenatal and postnatal erythropoiesis, respec-
tively, are presented (left). Quantifications of the
percentages of postnatal Glut1 cells are pre-
sented with each point representing an individual
mouse (right panel).
(C) The percentages of Gr1+ (left) and CD11b+ cells
(right) were quantified and data from individual
mice are presented with mean levels depicted by
a solid line. **p < 0.01; ***p < 0.001.
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commitment (Figure 6G).
2-DG Stimulates Erythroid Commitment by Increasing
Flux through the PPP
Glucose metabolism maintains the energetic balance in cells
via glycolysis and OXPHOS. While the basal oxygen con-
sumption rate (OCR), an estimation of OXPHOS, was not
modulated by lineage differentiation at early time points, the
induction of erythropoiesis significantly increased spare respi-
ratory capacity (SRC; Figure 7A). SRC allows a cell to pro-
duce energy under conditions of stress and is thought to pro-Cell Stem Cell 15, 169–1mote survival (Pearce et al., 2009; van
der Windt and Pearce, 2012).
Glycolysis was also increased during
early stages of erythroid commitment,
as noted by the extracellular acidifica-
tion rate (ECAR), glycolytic flux, and
lactate production (Figure 7B). Thus,
erythroid commitment of HSCs was
associated with enhanced OXPHOS as
well as glycolysis. In contrast, 2-DG
treatment was associated with an
increased SRC, but not glycolysis (Fig-
ures 7A and 7B). Because late-stage
erythropoiesis is associated with a loss
of mitochondrial membrane potential
and ROS production (Figure S6), it was
not surprising to find a decreased basal
respiration and SRC by day 7 of
erythroid differentiation, in both control
and 2-DG conditions (Figure 7A). Inter-estingly though, ATP levels were even lower in 2-DG-treated
progenitors, suggesting that neither optimal glycolysis nor en-
ergy production are limiting during the erythroid differentiation
process.
These data led to our hypothesis that 2-DG might function
to divert glucose from glycolysis into alternative pathways
stimulated by EPO. Glucose is broken down for use in glycolysis
and cellular respiration (via the TCA cycle), but it can also be
shunted through the PPP, providing five-carbon sugars for
nucleotide production. Importantly, we detected a striking
4-fold increase in pentose phosphates, likely ribose phos-
phate, in EPO-stimulated cells, and these levels were further84, August 7, 2014 ª2014 Elsevier Inc. 177
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panel). It was therefore of great interest to determine whether the
diversion of glucose to PPP is critical for erythroid commitment.
To this end, glucose-6-phosphate dehydrogenase (G6PD), the
enzyme that initiates the PPP, was inhibited with 6-amino-nico-
tinamide (6-AN) in the presence or absence of 2-DG (Figure 7C).
Notably, in both conditions, 6-AN completely abrogated EPO-
induced erythropoiesis, demonstrating that 2-DG promotes
erythropoiesis by shunting glucose-6-phosphate (G6P) through
the PPP (Figure 7D). The ensemble of these experiments unveils
a critical role of nucleotide biosynthesis, requiring contributions
from both glutamine and glucose catabolism, in the engagement
of hematopoietic progenitors to an erythroid fate.
DISCUSSION
Glucose and glutamine are subject to multiple catabolic and
biosynthetic fates. Here, we show that their processing is a
critical regulator of HSC differentiation. Our data identify a meta-
bolic switch that conditions lineage commitment. Erythroid
lineage specification of HSCs was completely dependent on
glutamine transport and metabolism. Under conditions where
glutamine utilization was blocked, HSCs were skewed to a mye-
lomonocytic cell fate, even in the presence of erythropoietin.
Using DON, a glutamine analog that blocks multiple glutamine-
utilizing enzymes, we were able to determine the pathways
that are essential for erythroid differentiation. Metabolic tracing
experiments demonstrated that DON efficiently blocked the
utilization of carbons/nitrogens from glutamine in the generation
of TCA cycle intermediates as well as in nucleotide synthesis.
The DON-mediated inhibition of differentiation was not due to
an insufficient replenishment of the TCA cycle; supplementing
these progenitors with a cell-permeable aKG did not restore
erythropoiesis. Rather, it was the generation of nucleotides
that was essential, with extracellular nucleosides promoting
erythroid differentiation (see model, Figure 7E).
We were initially surprised to find that 2-DG, a glucose analog
that inhibits glycolysis, enhanced HSC erythroid commitment.
Moreover, the injection of 2-DG into mice inhibited in vivo
myeloid differentiation but erythroid lineage specification was
sustained, even under stress conditions of anemia and during
the newborn period. These data suggested that EPO may stim-Figure 6. Glutamine-Dependent Nucleotide Biosynthesis Is a Rate-Lim
matopoietic Progenitors
(A) Tracing of [13C5,
15N2]glutamine in hematopoietic progenitors was carried out
butions of aKG isotopomers in each condition (±SD) are shown. The production
incorporation.
(B) A schematic representation of glutamine conversion to a-ketoglutarate (aKG) w
inhibitors shown in red (left).
(C) Expression of the GLS and GDH enzymes were monitored by qRT-PCR and
(D) rEPO-induced erythropoiesis wasmonitored after transaminases were blocked
of GlyA, CD71, and CD36 erythroid markers are shown at day 6 of differentiation
(E) The contribution of glutamine synthetase (GS)-derived glutamine in supportin
absence of glutamine (GLN) or in the absence of GLN and presence of the GS inhib
markers are shown at day 6 of differentiation.
(F) The de novo synthesis of UTP and ATP was monitored as a function of 15N/13C
was monitored by HPLC-MS and is presented as a percentage relative to that d
(G) The contribution of glutamine-derived aKG and nucleotide biosynthesis in e
cultured in the presence of DON with DMK or nucleosides. Expression levels of t
representative histograms are shown.
Culate specific metabolic pathways in HSCs that divert glucose
from glycolysis. Notably, early during erythroid differentiation,
pentose phosphate precursors for nucleotide biosynthesis
were already augmented by 4- to 5-fold as compared with un-
differentiated cells, and in the presence of 2-DG, levels were
increased by 8- to 10-fold. In this regard, it is interesting to
note that while 2-DG is reported to be nonmetabolizable (Sols
and Crane, 1954), it is phosphorylated by hexokinase to form
2-DG-6-phosphate (2-DG-6P) and, at least in red cells, may
proceed through the first reaction in the PPP via glucose-6P-
dehydrogenase (Suzuki et al., 1983). Furthermore, in tumor
cell lines, the accumulation of 2-DG-6P can promote the PPP
(Miwa et al., 2013; Sandulache et al., 2011). Our data show
that in hematopoietic progenitors, 2-DG increases the shunting
of glucose through the PPP to levels even higher that those
induced by rEPO alone. This can then result in further
de novo nucleotide biosynthesis and, in accord with the gluta-
mine metabolism data, promote the erythroid specification of
HSCs.
Oncogenic transformation and physiological activation have
been associated with an increased nutrient uptake and a diver-
sification in the types of nutrients that can be utilized by the
cell. Oncogenes such as Myc directly stimulate glutamine
catabolism by upregulating glutaminase (Gao et al., 2009; Le
et al., 2012), and during oncogenic transformation there is an
alteration in the relative dependence on glutamine consumption
(Chen and Russo, 2012; DeBerardinis et al., 2007; Gaglio et al.,
2011; Liu et al., 2012; Reynolds et al., 2014; Wise et al., 2008).
The utilization of these nutrients can also be coordinated; gluta-
mine uptake is coupled to glucose metabolism in certain
cellular systems (Wellen et al., 2010). Nevertheless, it is only
more recently that we have appreciated the importance of spe-
cific intermediates of these pathways in regulating both physi-
ological and pathological cellular processes (Fendt et al., 2013;
Lyssiotis et al., 2013; Selak et al., 2005; Son et al., 2013; Tan-
nahill et al., 2013). The data that we present here indicate that
HSC lineage specification requires an intricate coordination in
the processing of glucose and glutamine to the different meta-
bolic pathways. The precise mechanisms controlling this bal-
ance remain to be determined, but it is interesting to note
that one degree of regulation likely occurs at the level of
expression of the enzymes involved in these pathways. Bothiting Step in EPO-Induced Erythroid Differentiation of Human He-
for 24 hr after 3 days of differentiation in the indicated conditions. The distri-
of alanine (ALA) from the glutamine tracer was monitored as a function of 15N
ith key enzymes indicated in blue and the DON and aminooxyacetic acid (AOA)
mean values relative to actin ± SD are presented.
with AOA (1mM) in the absence or presence of DMK (7mM). Expression levels
.
g erythropoiesis was assessed in rEPO-stimulated progenitors cultured in the
itor methionine sulfoximine (MSO). Expression levels of GlyA, CD71, and CD36
incorporation in UTP and 15N incorporation in ATP. The consumption of serine
etected in expansion conditions.
rythropoiesis was assessed by supplementing EPO-induced progenitor cells
he GlyA, CD71, and CD36 erythroid markers were monitored after 6 days and
ell Stem Cell 15, 169–184, August 7, 2014 ª2014 Elsevier Inc. 179
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lated at early time points following EPO-induced erythropoiesis
(Figure 6C).
Glutamine is transported via ASCT2 as well as by members of
the SLC38 sodium-coupled neutral amino acid transporters
(SNAT) (reviewed in Fuchs and Bode, 2005; Kaadige et al.,
2010). The ASCT2 transporter plays a major role in HSCs; its
knockdown resulted in a 40%–75% decrease in glutamine up-
take and inhibited erythroid differentiation (data not shown and
Figure 1), but interestingly, the CD98 transporter, a heterodimer
of SLC3A2 and SLC7A5, is also upregulated during erythropoi-
esis (data not shown). This latter transporter has been shown
to regulate leucine uptake in T lymphocytes, and its deletion
severely impairs T cell expansion and effector differentiation
(Sinclair et al., 2013). It will therefore be of interest to determine
whether the CD98-mediated uptake of leucine and other amino
acids modulates HSC commitment.
The importance of distinct energy sources in regulating the
differentiation of hematopoietic cells has recently been demon-
strated in T lymphocytes. Effector T cells show high rates of
glycolysis, whereas suppressive regulatory T cells (Tregs) are
more dependent on FAO. Consistent with these data, blocking
FAO only impairs the differentiation of Tregs (Michalek et al.,
2011; Shi et al., 2011), whereas the maintenance of long-lived
memory T cells depends on a switch in energy metabolism
from glucose to fatty acid utilization (Pearce et al., 2009; van
der Windt and Pearce, 2012). Finally, an exciting recent study
has shown that changing the nutrient fuels of pluripotent stem
cells from glucose to lactate significantly enhances the genera-
tion of cardiomyocytes (Tohyama et al., 2013).
In our study, all inhibitors of glutaminolytic pathways pushed
EPO-stimulated progenitors toward a myelomonocytic cell
fate, as assessed by acquisition of the CD11b and CD13myeloid
markers (Figure 2). This effect was unlikely due to the loss of
bipotential progenitors with erythroid and myeloid potential,
because DON also inhibited the erythroid differentiation of
individual clones (Figure S7). Furthermore, the trend to amyeloid
differentiation was also observed in progenitors where erythroid
differentiation was not induced, with the vast majority of cells
acquiring these myeloid markers. Thus, inhibiting glutamine
metabolism favors myelomonocytic differentiation and is in-
compatible with erythroid commitment.
The findings reported here demonstrate the central role of
carbon and nitrogen metabolism in the lineage commitment of
hematopoietic stem/progenitor cells. We found that erythroid
specification is oriented by the processing of glucose and
glutamine through specific metabolic pathways. Furthermore,Figure 7. 2-DG Enhances Erythropoiesis by Induction of the Pentose P
(A) Basal and maximal oxygen consumption rates (OCRs) and extracellular acidifi
induced differentiation, in the absence or presence of 2-DG. Mean levels ± SEM
(B) Glucose consumption, lactate secretion, and intracellular ATP levels weremon
in expansion conditions (blue histograms) or as absolute peak values.
(C) Schematic representation of glycolysis in the presence of 2-DG and presen
presence of pentose phosphates in the different conditions was assessed by HPL
detected in expansion conditions ±SD.
(D) The effect of the glucose-6-phosphate-dehydrogenase (G6PD) inhibitor, 6
Expression levels of the GlyA, CD71, and CD36 erythroid differentiation markers
(E)Model depicting the critical role of glutamine and glucose reprogramming in nuc
2-DG in promoting the generation of pentose phosphates is presented.
Cwe show that the lineage commitment of HSCs can be modu-
lated by the expression of glucose and glutamine nutrient
transporters. It will be important to study whether glucose and
glutamine processing is differentially regulated in the in vivo hyp-
oxic niche where HSCs are found. This is particularly pertinent
because stemness is fostered by the environment of this niche,
resulting in a specific metabolic state within HSCs (Takubo
et al., 2013; Tohyama et al., 2013; Yu et al., 2013). Our elucida-
tion that erythroid specification occurs only when nucleotide
biosynthesis is promoted by intracellular glutamine availability
and the shunting of glucose through the PPP identifies a
regulation of HSC fate. Interventions modulating the utilization
of glucose and glutamine intermediates toward nucleotide
biosynthesis versus energy production may therefore lead
to the development of therapies directing HSC lineage
commitment.EXPERIMENTAL PROCEDURES
CD34+ Isolations and Ex Vivo Differentiation Assays
CD34+ cells were isolated from umbilical cord (UC) blood obtained immedi-
ately following delivery of full-term infants after informed consent and
approval. CD34+ cells were isolated by positive selection (StemCell Technolo-
gies Inc; MACS Miltenyi Biotec) according to the manufacturers’ recommen-
dations. For further purification of CD34+Lin or CD34+CD38Lin cells,
selected cells were stained with an anti-CD38 mAb and FACS-sorted on a
FACSAria. Progenitors were expanded in StemSpan media (StemCell Tech-
nologies Inc) supplemented with 5% fetal bovine serum (FBS), 25 ng/ml
rhuSCF (Amgen), 10 ng/ml rhuIL-3, and 10 ng/ml rhuIL-6 (Peprotech). For
experiments performed in the absence of glutamine, cells were differentiated
in IMDM media without glutamine (PAN BIOTECH) supplemented with BSA
(1.5 g/l, Roche), human holo-transferrin (60 mg/l, Sigma-Aldrich), human
insulin (4.4 mg/l, Sigma-Aldrich), rhuSCF (25 ng/ml, Amgen), rhuIL-3 (25 ng/
ml), and rhuIL-6 (10 ng/ml, Peprotech). Erythropoiesis was induced by addition
of 3 U/ml recombinant human erythropoietin (rEPO) (Eprex, Janssen-Cilag).
Glutamine utilization was blocked, as indicated, by addition of DON (50 mM;
Sigma-Aldrich) or AOA (1 mM, Sigma-Aldrich) and rescue experiments were
performed in the presence of DMK (7 mM, Sigma-Aldrich) or Embryomax
nucleosides mix (Merck-Millipore). GS was blocked by MSO (1 mM, Sigma-
Aldrich). Glucose utilization was blocked by addition of 2-DG (0.2–2.5 mM,
as indicated, Sigma-Aldrich). Cultures were supplemented with analogs or
inhibitors every 3 days.
Flow Cytometry
Cells were stained with fluorochrome-conjugated mAbs directed against
CD11b, CD13, CD36, a4 integrin, and GlyA (Beckman Coulter). Surface
Glut1 expression was monitored as a function of binding to its ligand, the
envelope glycoprotein of the human T lymphotrophic virus (HTLV). A recom-
binant HTLV envelope receptor binding domain (HRBD) fused to either a rab-
bit Fc tag (HRBDrFc) or the EGFP coding sequence was used as previously
described (Manel et al., 2003; Montel-Hagen et al., 2008b). Surface ASCT2hosphate Pathway
cation rates (ECARs) were determined at days 3 and 7 of expansion and rEPO-
are presented.
itored by HPLC-MS and are presented as a percentage relative to that detected
tation of the pentose phosphate shunt from glucose-6-phosphate (G6P). The
C-MS at day 4 of differentiation and is presented as a percentage relative to that
-amino-nicotinamide (6-AN) on EPO-induced erythropoiesis was assessed.
were monitored at day 6 and representative histograms are shown.
leotide biosynthesis during EPO-induced erythroid differentiation. The effect of
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to its ligand, the RD114 envelope glycoprotein of the feline endogenous
retrovirus (Laval et al., 2013), fused to a murine Fc tag and revealed with
an Alexa-Fluor-647-conjugated anti-mouse IgG (Invitrogen). Mitochondrial
biomass, transmembrane potential, and ROS levels were monitored by stain-
ing with Mitotracker green, Mitotracker red, and Rhodamine 123, respec-
tively (Invitrogen). Data analyses were performed using FlowJo software
(Tree Star).
Quantitative Real-Time PCR
Total RNA was isolated at the indicated time points using the RNeasy Mini kit
(QIAGEN) and qPCR of cDNAs performed using the Quantitect SYBR green
PCR Master mix (Roche). Primer sequences are provided in the Supplemental
Experimental Procedures. Amplification of cDNAs was performed using the
LightCycler 480 (Roche). Relative expression was calculated by normalization
to 18S or b-actin as indicated.
Virus Production and Transduction of CD34+CD38–Lin– HSCs
and CD34+CD38+ Progenitor Cells
shGlut1-GFP and shASCT2-GFP vectors were generated as described in the
Supplemental Experimental Procedures and lentiviral virions were produced
by transient transfection of 293T cells with a three vector packaging system,
as described previously (Loisel-Meyer et al., 2012). For progenitor transduc-
tion, cells were stimulated for 12 hr with rhuSCF (25 ng/ml), rhuIL-3 (10 ng/ml),
and rhuIL-6 (10 ng/ml) and then FACS-sorted as a function of CD38 and GFP
expression, as shown. For transduction of bulk CD34+ progenitors (5 3 105),
cells were stimulated for 3 days and then exposed to viral supernatants con-
taining 4.8 3 105 TU to 9.9 3 105 TU. Following transduction, cytokines
were added as indicated and erythroid differentiation was initiated by the
addition of rEPO (3 U/ml; indicated as day 0).
Induction of Anemia and In Vivo Modulation of Glucose
and Glutamine Catabolism
Anemia was induced in adult C57Bl/6 mice by injection of 40 mg/kg PHZ on
days 0, 1, and 3. 2-DG (0.5 g/kg) or DON (1.5 mg/kg) was injected at days 2
and 4 and animals were euthanized on day 5. Newborn mice were injected
with 2-DG (0.25 g/kg) or DON (0.75 mg/kg) at days 3 and 5 of life and sacrificed
at day 6.
Liquid Chromotography Mass Spectrometry
For profiling of intracellular metabolites, cells (1 3 106) were incubated in
IMDM without glutamine and were supplemented with uniformly labeled
[U-13C5-
15N2]glutamine for 24 hr. Cells were rapidly washed in ice-cold
PBS and metabolites were extracted in a 50% methanol/30% acetonitrile/
20% water solution. For profiling of metabolite exchange rates, cells were
cultured in the same conditions and media derived from wells devoid of cells
were used as a reference. All cultures were performed in triplicate. Both cell
extracts and media were centrifuged at 16,000 3 g for 10 min at 4C and su-
pernatants were analyzed by HPLC-MS. Samples were separated on a
Thermo Scientific Accela liquid chromatography system coupled with a
guard column (Hichrom) and a ZIC-pHILIC column (Merck). The separation
was performed using a gradient elution in a solution of 20 mM ammonium
carbonate, with 0.1% ammonium hydroxide and acetonitrile. Metabolites
were detected using a Thermo Scientific Exactive Orbitrap mass spectrom-
eter with electrospray ionization, operating in a polarity switching mode. The
raw data were analyzed with Xcalibur 2.2 and LCquan 2.7 Thermo scientific
software. The peak areas resulting from the intracellular samples were
normalized to the number of cells obtained at the end of the 24 hr incubation
period.
Flux Analysis
OCRs and ECARs were measured using the XF-24 Extracellular Flux Analyzer
(Seahorse Bioscience). For the measurement of the OCR, cells (0.75–1.106)
were placed in XF media (nonbuffered DMEM containing 2.5 mM glucose,
2 mM glutamine, and 1 mM sodium pyruvate) and monitored in basal condi-
tions and maximal conditions. ECARs were monitored in XF media (DMEM
containing 2 mM glutamine) in response to 10 mM glucose.182 Cell Stem Cell 15, 169–184, August 7, 2014 ª2014 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes seven figures and Supple-
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